English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hepatitis C virus (HCV) RNA quantification is extensively used for therapeutic management of HCV chronic infection (1). The COBAS HCV Monitor v2.0 assay (HCM) was until recently one of the most used quantification methods worldwide. Two of its drawbacks are the labor-intensive manual extraction of HCV RNA and the frequent requirement of serum dilution for accurate quantification (>5.7 log10 IU/ml) (4). The COBAS Ampliprep TNAI/COBAS TaqMan 48 Roche assay (CAPP-CTM) combines automated HCV RNA extraction with real-time PCR on the COBAS TaqMan 48 instrument (CTM48). It is one of the first platforms for clinical laboratories tending towards fully automated nucleic acid isolation and quantification, and it ensures a broad dynamic quantification range (43 to 69,000,000 IU/ml).

journal of clinical microbiology

Broad Differences between the COBAS Ampliprep Total Nucleic Acid Isolation-COBAS TaqMan 48 Hepatitis C Virus (HCV) and COBAS HCV Monitor v2.0 Assays for Quantification of Serum HCV RNA of Non-1 Genotypes